These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 26964917)

  • 1. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
    Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
    J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
    Kesavan M; Turner JH; Meyrick D; Yeo S; Cardaci G; Lenzo NP
    Cancer Biother Radiopharm; 2018 Sep; 33(7):274-281. PubMed ID: 29989440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
    Flippot R; Telli T; Velev M; Fléchon A; De Vries-Brilland M; Turpin L; Bergman A; Turco F; Mahammedi H; Fendler WP; Giraudet AL; Josset Q; Montravers F; Vogel W; Gillessen S; Berardi Vilei S; Herrmann K; Kryza D; Paone G; Hadaschik B; Merlin C; Dufour PA; Bernard-Tessier A; Naoun N; Patrikidou A; Garcia C; Foulon S; Pagès A; Fizazi K
    Eur Urol Oncol; 2024 Oct; 7(5):1132-1140. PubMed ID: 38664139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Outcomes and Predictive Biomarkers for
    Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
    Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.
    Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):352-360. PubMed ID: 28440324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of PSMA-Targeted Molecular Radioligand Therapy with
    Calais J; Czernin J; Thin P; Gartmann J; Nguyen K; Armstrong WR; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Dahlbom M; He B; Esfandiari R; Ranganathan D; Herrmann K; Eiber M; Fendler WP; Delpassand E
    J Nucl Med; 2021 Oct; 62(10):1447-1456. PubMed ID: 34272322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with
    Calais J; Gafita A; Eiber M; Armstrong WR; Gartmann J; Thin P; Nguyen K; Lok V; Gosa L; Grogan T; Esfandiari R; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Ranganathan D; Slavik R; Dahlbom M; Herrmann K; Delpassand E; Fendler WP; Czernin J
    J Nucl Med; 2021 Oct; 62(10):1440-1446. PubMed ID: 34016732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 17. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
    Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
    Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of novel PSMA-targeting [
    Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2794-2805. PubMed ID: 38658392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RECIP 1.0 Predicts Progression-Free Survival After [
    Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
    J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.